Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 12/20 | 0.48 |
| ▸ | ADRB1 | P08588 | 4/20 | 0.48 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.48 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.48 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.46 |
| ▸ | CASR | P41180 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10770012 | 1.00 | ADRB3 (0.48) | ADRB3ADRB1ADRB2ADRA1DADRA1A | |
| Hydrochloric Acid SCHEMBL10766903 | 0.99 | ADRB3 (0.49) | ADRB3ADRB1ADRB2ADRA1DADRA1A | |
| Hydrochloric Acid SCHEMBL10766900 | 0.99 | ADRB3 (0.49) | ADRB3ADRB1ADRB2ADRA1DADRA1A | |
| SCHEMBL8855298 | 0.89 | ADRB2 (0.52) | ADRB3ADRB1ADRB2ADRA1DADRA1A | |
| SCHEMBL11460997 | 0.88 | CYP2D6 (0.42) | ADRB3ADRB1ADRB2ADRA1DADRA1A | |
| SCHEMBL10730192 | 0.88 | PARP10 (0.55) | ADRB3ADRB1ADRB2CASR | |
| SCHEMBL11134654 | 0.87 | ADRB3 (0.47) | ADRB3ADRB1ADRB2CASRKDM4E | |
| Hydrochloric Acid SCHEMBL8855321 | 0.87 | PARP10 (0.54) | ADRB3ADRB1ADRB2CASR | |
| SCHEMBL11132780 | 0.86 | ADRB3 (0.47) | ADRB3ADRB1ADRB2CASRKDM4E | |
| Acetic Acid SCHEMBL11451850 | 0.84 | ADRB2 (0.50) | ADRB3ADRB1ADRB2CASRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0241618-A2 | Phenyl ethanol amine derivative for use as an oncolytic medicament | ELI LILLY AND COMPANY (US) | 1987-10-21 | — | — | EP | claimed |
| EP-0104888-B1 | PROCESS FOR PREPARING 2-HYDROXY-2-PHENYLETHYLAMINES | ELI LILLY AND COMPANY (US) | 1986-10-15 | — | — | EP | claimed |
| EP-0104888-A1 | Process for preparing 2-hydroxy-2-phenylethylamines | ELI LILLY AND COMPANY (US) | 1984-04-04 | — | — | EP | claimed |
| EP-0007206-B1 | PHENETHANOLAMINES, THEIR FORMULATIONS, PREPARATION AND USE | ELI LILLY AND COMPANY (US) | 1983-02-23 | — | — | EP | claimed |
| EP-0007206-A1 | Phenethanolamines, their formulations, preparation and use | ELI LILLY AND COMPANY (US) | 1980-01-23 | — | — | EP | claimed |
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-01-14 | — | — | US | disclosed |
| US-20080161324-A1 | Compositions and methods for treatment of viral diseases | EXCRX (SINGAPORE) PTE. LTD. (F.K.A. COMBINATORX (SINGAPORE) PTE LTD.) (SG) | 2008-07-03 | — | — | US | disclosed |
| WO-2008033466-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PRE. LTD. (SG) | 2008-03-20 | — | — | WO | disclosed |
| EP-0241618-A2 | Phenyl ethanol amine derivative for use as an oncolytic medicament | ELI LILLY AND COMPANY (US) | 1987-10-21 | — | — | EP | disclosed |
| EP-0104888-B1 | PROCESS FOR PREPARING 2-HYDROXY-2-PHENYLETHYLAMINES | ELI LILLY AND COMPANY (US) | 1986-10-15 | — | — | EP | disclosed |
| EP-0047536-B1 | SUBSTITUTED PROPYLAMINES | ELI LILLY AND COMPANY (US) | 1984-06-27 | — | — | EP | disclosed |
| EP-0104888-A1 | Process for preparing 2-hydroxy-2-phenylethylamines | ELI LILLY AND COMPANY (US) | 1984-04-04 | — | — | EP | disclosed |
| EP-0007206-B1 | PHENETHANOLAMINES, THEIR FORMULATIONS, PREPARATION AND USE | ELI LILLY AND COMPANY (US) | 1983-02-23 | — | — | EP | disclosed |
| EP-0047536-A2 | Substituted propylamines | ELI LILLY AND COMPANY (US) | 1982-03-17 | — | — | EP | disclosed |
| EP-0007206-A1 | Phenethanolamines, their formulations, preparation and use | ELI LILLY AND COMPANY (US) | 1980-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | HTR1A, HTR3B, HTR3A | ADRB3 141/4885ADRB1 199/4885ADRB2 277/4885 |
| US-20080161324-A1 | Compositions and methods for treatment of viral diseases | HAVCR2, EIF2AK2, RNASE1 | ADRB3 2895/4885ADRB1 3011/4885ADRB2 4192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.